Shopping Cart
Remove All
Your shopping cart is currently empty
Henatinib is an orally active small molecule multi-kinase inhibitor with broad antitumour effects. henatinib inhibits the activity of VEGFR-2 (IC50: 0.6 nM), c-kit (IC50: 3.3 nM), PDGFR (IC50: 41.5 nM). henatinib significantly inhibits VEGFR-2 phosphorylation and its downstream signalling pathways in human umbilical vein endothelial cells (HUVECs). Henatinib significantly inhibited VEGFR-2 phosphorylation and its downstream signaling pathway in human umbilical vein endothelial cells (HUVECs).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $2,140 | 8-10 weeks | 8-10 weeks | |
| 50 mg | $2,785 | 8-10 weeks | 8-10 weeks | |
| 100 mg | $3,520 | 8-10 weeks | 8-10 weeks |
| Description | Henatinib is an orally active small molecule multi-kinase inhibitor with broad antitumour effects. henatinib inhibits the activity of VEGFR-2 (IC50: 0.6 nM), c-kit (IC50: 3.3 nM), PDGFR (IC50: 41.5 nM). henatinib significantly inhibits VEGFR-2 phosphorylation and its downstream signalling pathways in human umbilical vein endothelial cells (HUVECs). Henatinib significantly inhibited VEGFR-2 phosphorylation and its downstream signaling pathway in human umbilical vein endothelial cells (HUVECs). |
| Targets&IC50 | VEGFR2:0.6 nM |
| Molecular Weight | 468.52 |
| Formula | C25H29FN4O4 |
| Cas No. | 1239269-51-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.